{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:15:00Z","timestamp":1794737700594,"version":"4.9.1"},"reference-count":167,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.eururo.2021.08.010","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T23:50:52Z","timestamp":1631231452000},"page":"75-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1541,"title":["European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)"],"prefix":"10.1016","volume":"81","author":[{"given":"Marko","family":"Babjuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dominguez Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Hugh","family":"Mostafid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2021.08.010_bib0005","series-title":"Oxford Centre for Evidence-based Medicine levels of evidence. Updated by Jeremy Howick, March 2009","author":"Phillips","year":"2009"},{"key":"10.1016\/j.eururo.2021.08.010_bib0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2021.08.010_bib0015","series-title":"Estimated number of new cases in 2020, worldwide, both sexes, all ages","author":"International Agency for Research on Cancer","year":"2021"},{"key":"10.1016\/j.eururo.2021.08.010_bib0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2013.10.001","article-title":"International variations in bladder cancer incidence and mortality","volume":"66","author":"Chavan","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-015-1739-2","article-title":"Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old","volume":"466","author":"Comperat","year":"2015","journal-title":"Virch Arch"},{"key":"10.1016\/j.eururo.2021.08.010_bib0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/ije\/dyw044","article-title":"Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies","volume":"45","author":"van Osch","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00420-013-0916-3","article-title":"Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines","volume":"87","author":"Pesch","year":"2014","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.eururo.2021.08.010_bib0040","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/ijc.29062","article-title":"The prognostic value of family history among patients with urinary bladder cancer","volume":"136","author":"Egbers","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2021.08.010_bib0045","first-page":"1499","article-title":"Association between APE1 Asp148Glu polymorphism and the risk of urinary cancers: a meta-analysis of 18 case-control studies","volume":"9","author":"Zhong","year":"2016","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.eururo.2021.08.010_bib0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/djx237","article-title":"Familial cancer clustering in urothelial cancer: a population-based case-control study","volume":"110","author":"Martin","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2021.08.010_bib0055","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/1055-9965.EPI-14-0059","article-title":"Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure","volume":"23","author":"Steinmaus","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.eururo.2021.08.010_bib0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00394-019-01907-8","article-title":"An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies","volume":"59","author":"Witlox","year":"2020","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.eururo.2021.08.010_bib0065","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/ijc.33008","article-title":"Fruit consumption and the risk of bladder cancer: a pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study","volume":"147","author":"Jochems","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2021.08.010_bib0070","doi-asserted-by":"crossref","first-page":"i1541","DOI":"10.1136\/bmj.i1541","article-title":"Pioglitazone use and risk of bladder cancer: population based cohort study","volume":"352","author":"Tuccori","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2021.08.010_bib0075","series-title":"International Union Against Cancer TNM classification of malignant tumors","first-page":"263","year":"2017"},{"key":"10.1016\/j.eururo.2021.08.010_bib0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0085","series-title":"WHO classification of tumours of the urinary system and male genital organs","author":"Moch","year":"2016"},{"key":"10.1016\/j.eururo.2021.08.010_bib0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.euf.2016.06.004","article-title":"Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer","volume":"4","author":"Colombo","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2021.08.010_bib0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2019.10.002","article-title":"Papillary urothelial neoplasm of low malignant potential (PUN-LMP): still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?","volume":"38","author":"Hentschel","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic Value of the WHO1973 and WHO2004\/2016 Classification Systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non\u2013muscle-invasive Bladder Cancer Guidelines Panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0110","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083192","article-title":"Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder","volume":"9","author":"Mangrud","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2021.08.010_bib0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskimae","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euf.2018.01.003","article-title":"Grading of urothelial carcinoma and the new \u201cWorld Health Organisation classification of tumours of the urinary system and male genital organs 2016\u201d","volume":"5","author":"Comperat","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2021.08.010_bib0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOU.0000000000000086","article-title":"Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection","volume":"24","author":"Seisen","year":"2014","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2021.08.010_bib0145","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bju.13345","article-title":"Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer","volume":"117","author":"Ramirez","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00261-017-1249-6","article-title":"Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results","volume":"43","author":"Trinh","year":"2018","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0155","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0160","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0022-5347(05)67137-6","article-title":"Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0165","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.soc.2014.06.001","article-title":"Recent advances in imaging cancer of the kidney and urinary tract","volume":"23","author":"Hilton","year":"2014","journal-title":"Surg Oncol Clin North Am"},{"key":"10.1016\/j.eururo.2021.08.010_bib0170","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0175","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2021.08.010_bib0180","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2008.193","article-title":"Diagnosis of urothelial carcinoma from urine","volume":"22","author":"Tetu","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0185","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0190","series-title":"The Paris system for reporting urinary cytology","author":"Rosenthal","year":"2016"},{"key":"10.1016\/j.eururo.2021.08.010_bib0195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/cncy.21999","article-title":"One year of experience using the Paris system for reporting urinary cytology","volume":"126","author":"Meilleroux","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0200","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1007\/s00345-018-2380-x","article-title":"An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0205","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.juro.2009.08.150","article-title":"Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial","volume":"183","author":"van der Aa","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0210","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.eururo.2018.11.055","article-title":"Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer","volume":"75","author":"Valenberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0215","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"D\u2019Andrea","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0220","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","article-title":"Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy","volume":"76","author":"Konety","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0225","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11136-016-1493-1","article-title":"How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial","volume":"26","author":"Krajewski","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2021.08.010_bib0230","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.14557","article-title":"Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour","volume":"123","author":"Suarez-Ibarrola","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0235","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2020.04.059","article-title":"An international collaborative consensus statement on en bloc resection of bladder tumour incorporating two systematic reviews, a two-round Delphi survey, and a consensus meeting","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0240","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1111\/j.1464-410X.2011.10904.x","article-title":"The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer","volume":"110","author":"Richterstetter","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0245","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2009.05.047","article-title":"Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience","volume":"57","author":"Mariappan","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0250","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1089\/end.2017.0154","article-title":"Holmium YAG photocoagulation: safe and economical alternative to transurethral resection in small nonmuscle-invasive bladder tumors","volume":"31","author":"Planelles Gomez","year":"2017","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0255","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000019859","article-title":"Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee","volume":"35","author":"van der Meijden","year":"1999","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0260","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0265","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2005.05.021","article-title":"Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder","volume":"48","author":"Mungan","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0270","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1007\/s00345-019-02673-2","article-title":"Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer","volume":"37","author":"Brant","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S0266462310001364","article-title":"Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis","volume":"27","author":"Mowatt","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.eururo.2021.08.010_bib0280","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.urolonc.2014.04.005","article-title":"Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology","volume":"32","author":"Neuzillet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0285","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.eururo.2009.09.037","article-title":"Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy","volume":"57","author":"Draga","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0290","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1464-410X.2009.08839.x","article-title":"Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin","volume":"105","author":"Ray","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0295","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.juro.2016.10.061","article-title":"Comparative effectiveness of fluorescent versus white light cystoscopy for initial diagnosis or surveillance of bladder cancer on clinical outcomes: systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0300","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4111\/icu.2018.59.2.98","article-title":"Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: prospective, randomized comparison with white light cystoscopy","volume":"59","author":"Kim","year":"2018","journal-title":"Invest Clin Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0305","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"Naito","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0310","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","article-title":"Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review","volume":"73","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0315","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2021.08.010_bib0320","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0325","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.euf.2017.10.004","article-title":"Long-term outcomes from re-resection for high-risk non-muscle-invasive bladder cancer: a potential to rationalize use","volume":"5","author":"Gordon","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2021.08.010_bib0330","doi-asserted-by":"crossref","first-page":"E306","DOI":"10.5489\/cuaj.1514","article-title":"Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer","volume":"8","author":"Bishr","year":"2014","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2021.08.010_bib0335","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","article-title":"Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought","volume":"36","author":"Palou","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/grade 3 bladder cancer treated with bacille Calmette-Guerin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0345","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/bju.13102","article-title":"Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical bacillus Calmette-Guerin","volume":"116","author":"Baltaci","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0350","series-title":"Urinary tract carcinomas \u2013 biopsy and transurethral resection specimen","author":"Grignon","year":"2019"},{"key":"10.1016\/j.eururo.2021.08.010_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","article-title":"Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation","volume":"34","author":"Lammers","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0365","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0370","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0375","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0380","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.euf.2018.12.002","article-title":"Urothelial carcinoma in bladder diverticula: a multicenter analysis of characteristics and clinical outcomes","volume":"6","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2021.08.010_bib0385","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0974-7796.84954","article-title":"Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical bacille Calmette-Guerin","volume":"3","author":"Alkhateeb","year":"2011","journal-title":"Urol Ann"},{"key":"10.1016\/j.eururo.2021.08.010_bib0395","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2021.08.010_bib0400","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0405","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0410","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2012.08.057","article-title":"Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer","volume":"62","author":"Rink","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0415","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2013.06.010","article-title":"Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature","volume":"65","author":"Crivelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0420","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/01.ju.0000168657.51551.49","article-title":"Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer","volume":"174","author":"Brocks","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0425","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0430","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0435","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0440","doi-asserted-by":"crossref","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","article-title":"Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Abern","year":"2013","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eururo.2021.08.010_bib0445","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0450","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2021.08.010_bib0455","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00345-019-02628-7","article-title":"Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors","volume":"37","author":"Zhou","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0460","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0022-5347(05)65468-7","article-title":"Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo","volume":"167","author":"Bohle","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0465","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0022-5347(01)66226-8","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0470","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2021.08.010_bib0475","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0480","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0485","doi-asserted-by":"crossref","first-page":"400.e7","DOI":"10.1016\/j.urolonc.2018.05.026","article-title":"An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups","volume":"36","author":"Bosschieter","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0490","doi-asserted-by":"crossref","first-page":"179.e9","DOI":"10.1016\/j.urolonc.2018.10.019","article-title":"The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: a preliminary results of randomized controlled trial","volume":"37","author":"Elsawy","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0495","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2021.08.010_bib0500","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1464-410X.1989.tb05159.x","article-title":"Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times","volume":"63","author":"Giesbers","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0505","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.eururo.2003.12.010","volume":"45","author":"Kuroda","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0510","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.juro.2014.03.101","article-title":"Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer","volume":"192","author":"Arends","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0515","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0520","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0525","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0530","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0535","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0540","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0545","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0550","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0555","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0560","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"Jarvinen","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0565","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0570","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0575","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.juro.2017.01.086","article-title":"Efficacy of bacillus Calmette-Guerin strains for treatment of nonmuscle invasive bladder cancer: a systematic review and network meta-analysis","volume":"198","author":"Boehm","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0580","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0585","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/bju.14793","article-title":"The epidemiology of bacille Calmette-Guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study","volume":"124","author":"Larsen","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0595","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0600","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.acuro.2017.10.003","article-title":"Safety and efficacy of various strains of bacille Calmette-Guerin in the treatment of bladder tumours in standard clinical practice","volume":"42","author":"Unda-Urzaiz","year":"2018","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.eururo.2021.08.010_bib0605","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/21681805.2018.1538162","article-title":"Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer \u2013 a follow-up five years after the start of treatment","volume":"52","author":"Danielsson","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0610","doi-asserted-by":"crossref","first-page":"E658","DOI":"10.1111\/j.1464-410X.2012.11405.x","article-title":"Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria","volume":"110","author":"Herr","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0615","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/tri.12484","article-title":"Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy","volume":"28","author":"Roumeguere","year":"2015","journal-title":"Transplant Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0620","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eursup.2008.08.001","article-title":"Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events","volume":"7","author":"Witjes","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2021.08.010_bib0625","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0630","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0635","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0640","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette-Guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013","volume":"68","author":"Martinez-Pineiro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0645","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0650","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0655","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Martinez-Pineiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0660","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0665","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0670","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2019.00121","article-title":"Combination of intravesical bacille Calmette-Guerin and chemotherapy vs. bacille Calmette-Guerin alone in non-muscle invasive bladder cancer: a meta-analysis","volume":"9","author":"Huang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0675","article-title":"Intravesical bacillus Calmette-Guerin with interferon-alpha versus intravesical bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer","volume":"2017","author":"Shepherd","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2021.08.010_bib0680","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","volume":"68","author":"Jarvinen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0685","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2016.03.034","article-title":"Intravesical bacillus Calmette-Guerin versus combination of epirubicin and interferon-alpha2a in reducing recurrence of non-muscle-invasive bladder carcinoma: FinnBladder-6 study","volume":"70","author":"Marttila","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0690","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0695","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1080\/21681805.2016.1210672","article-title":"Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder","volume":"50","author":"Kaasinen","year":"2016","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0700","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","article-title":"Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications","volume":"155","author":"Solsona","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0705","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2006.05.059","article-title":"Urothelial carcinoma of the prostate","volume":"69","author":"Palou","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0710","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.urolonc.2014.02.020","article-title":"BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study","volume":"33","author":"Herr","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0715","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0720","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0725","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0730","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0735","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"2012","author":"Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2021.08.010_bib0740","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"Electromotive drug administration (EMDA) of mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2021.08.010_bib0745","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0750","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0755","first-page":"44","article-title":"FDA approves pembrolizumab for BCG-unresponsive NMIBC","volume":"34","author":"Wright","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0760","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0765","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2021.08.010_bib0770","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2009.09.024","article-title":"Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort","volume":"57","author":"Fritsche","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0775","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1464-410X.2012.10939.x","article-title":"Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome","volume":"110","author":"Turker","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0780","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/bju.13146","article-title":"Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy","volume":"117","author":"Moschini","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2021.08.010_bib0785","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical outcomes of cT1 micropapillary bladder cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0790","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0795","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2005.12.029","article-title":"Watchful waiting policy in recurrent Ta G1 bladder tumors","volume":"49","author":"Gofrit","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0800","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0805","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","article-title":"Active surveillance for low risk nonmuscle invasive bladder cancer: a confirmatory and resource consumption study from the BIAS project","volume":"199","author":"Hurle","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0810","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0815","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","article-title":"A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database","volume":"173","author":"Mariappan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0820","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0825","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","article-title":"Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years?","volume":"61","author":"Holmang","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0830","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.juro.2016.12.010","article-title":"Performance characteristics of a multigene urine biomarker test for monitoring for recurrent urothelial carcinoma in a multicenter study","volume":"197","author":"Kavalieris","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2021.08.010_bib0835","doi-asserted-by":"crossref","first-page":"386.e15","DOI":"10.1016\/j.urolonc.2015.04.018","article-title":"Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1\u20132 bladder cancers: a matched-pair analysis","volume":"33","author":"Niwa","year":"2015","journal-title":"Urol Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821019783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283821019783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:10:43Z","timestamp":1759583443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283821019783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0302283821019783"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}